Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07593924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind, active controlled phase III clinical trial.
Trial Details
NCT Number NCT07593924
Lead Sponsor Sinovac Life Sciences Co., Ltd.
Conditions
(from sponsor)		 Pneumococcal Infectious Diseases
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov